Lisa R. Tannock, M.D. | Saha Cardiovascular Research Center

Lisa R. Tannock, M.D.

Connect
About
Education
Publications

Lisa.Tannock@uky.edu
859-323-5821
Charles T. Wethington Bldg 900 South Limestone St, Lexington, KY 40536-0200
Biosketch

Position(s):

Regular Faculty

Professor

Chief, Division of Endocrinology & Molecular Medicine

Affiliation(s):

Internal Medicine

Cardiovascular Research Center

Other Affiliation(s):

Internal Medicine - Endocrinology

CVRC - Core Faculty

Nutritional Sciences Graduate Faculty

Bio / Education:

University of Toronto, Toronto, Canada	MD	06/1994	Medicine
University of Toronto, Toronto, Canada	Residency	06/1997	Internal Medicine
University of Washington, Seattle, WA	Fellowship	06/2000	Endocrinology

Selected Publications:

1. Tannock LR, Little PJ, Wight TN, Chait A: Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced LDL binding. J Lipid Res 43:149-157, 2002. PMID:11792734.
2. Tannock LR, Little PJ, Tsoi C, Barrett PHR, Wight TN, Chait A: Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia. 47:837-843, 2004. PMID:15071727.
3. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 114:659-668, 2004. PMID:15343384 :PMC514580
4. Tannock LR, O’Brien KD, Knopp RH, Retzlaff B, Fish B, Wener MH, Kahn SE, Chait A: Cholesterol feeding increases CRP and SAA levels in lean, insulin sensitive subjects. Circulation 111:3058-3062, 2005. PMID:15939816.
5. Tannock LR, Kirk EA, King VL, LeBoeuf R, Wight TN, Chait A: Glucosamine Supplementation Accelerates Early but not Late Atherosclerosis in LDL Receptor Deficient Mice. J Nutr 136:2856-2861, 2006. PMID:17056813.

PubMed Publications:

Thompson, J.C.;Wilson, P.G.;Shridas, P.;Ji, A.;Beer, M.;Beer, F.C.;Webb, N.R.;Tannock, L.R. "Serum amyloid A3 is pro-atherogenic." Atherosclerosis 268, (2018): 32-35. [PubMed Link] | [ Full text ]
Tannock, L.R.;De Beer, M.C.;Ji, A.;Shridas, P.;Noffsinger, V.P.;Hartigh, L.;Chait, A.;Beer, F.C.;Webb, N.R. "Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein." Journal of lipid research 59, 2 (2018): 339-347. [PubMed Link] | [ Full text ]
Hager, M.R.;Narla, A.D.;Tannock, L.R. "Dyslipidemia in patients with chronic kidney disease." Reviews in endocrine & metabolic disorders 18, 1 (2017): 29-40. [PubMed Link] | [ Full text ]
Grandoch, M.;Kohlmorgen, C.;Melchior-Becker, A.;Feldmann, K.;Homann, S.;Müller, J.;Kiene, L.S.;Zeng-Brouwers, J.;Schmitz, F.;Nagy, N.;Polzin, A.;Gowert, N.S.;Elvers, M.;Skroblin, P.;Yin, X.;Mayr, M.;Schaefer, L.;Tannock, L.R.;Fischer, J.W. "Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis." Arteriosclerosis, thrombosis, and vascular biology 36, 5 (2016): e41-50. [PubMed Link] | [ Full text ]
Tannock, L.;DeGroot, L.J.;Chrousos, G.;Dungan, K.;Feingold, K.R.;Grossman, A.;Hershman, J.M.;Koch, C.;Korbonits, M.;McLachlan, R.;New, M.;Purnell, J.;Rebar, R.;Singer, F.;Vinik, A. "Dyslipidemia in Chronic Kidney Disease" (2000): [PubMed Link] |